These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38796422)

  • 1. Protocol for CHAMPION study: a prospective study of maximal-cytoreductive therapies for patients with de novo metastatic hormone-sensitive prostate cancer who achieve oligopersistent metastases during systemic treatment with apalutamide plus androgen deprivation therapy.
    Wang B; Pan J; Zhang T; Ni X; Wei Y; Li X; Fang B; Hu X; Gan H; Wu J; Wang H; Ye D; Zhu Y
    BMC Cancer; 2024 May; 24(1):643. PubMed ID: 38796422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease.
    Parikh NR; Huiza C; Patel JS; Tsai S; Kalpage N; Thein M; Pitcher S; Lee SP; Inouye WS; Jordan ML; Sanati H; Jafari L; Bennett CJ; Gin GE; Kishan AU; Reiter RE; Lewis M; Sadeghi A; Aronson WJ; Garraway IP; Rettig MB; Nickols NG
    BMC Cancer; 2019 Apr; 19(1):291. PubMed ID: 30935383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic and Tumor-directed Therapy for Oligorecurrent Metastatic Prostate Cancer (SATURN): Primary Endpoint Results from a Phase 2 Clinical Trial.
    Nikitas J; Rettig M; Shen J; Reiter R; Lee A; Steinberg ML; Valle LF; Sachdeva A; Romero T; Calais J; Czernin J; Nickols NG; Kishan AU
    Eur Urol; 2024 Jun; 85(6):517-520. PubMed ID: 38494380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LUNAR: a randomized Phase 2 study of
    Ma TM; Czernin J; Felix C; Alano R; Wilhalme H; Valle L; Steinberg ML; Dahlbom M; Reiter RE; Rettig MB; Cao M; Calais J; Kishan AU
    BJU Int; 2023 Jul; 132(1):65-74. PubMed ID: 36797449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).
    Shore N; Hafron J; Saltzstein D; Brown G; Belkoff L; Aggarwal P; Phillips J; Bhaumik A; McGowan T
    J Urol; 2024 Nov; 212(5):682-691. PubMed ID: 39088398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UpFrontPSMA: a randomized phase 2 study of sequential
    Dhiantravan N; Emmett L; Joshua AM; Pattison DA; Francis RJ; Williams S; Sandhu S; Davis ID; Vela I; Neha N; Bressel M; Murphy DG; Hofman MS; Azad AA
    BJU Int; 2021 Sep; 128(3):331-342. PubMed ID: 33682320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
    Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy.
    Nikitas J; Gafita A; Benz MR; Djaïleb L; Farolfi A; Hotta M; Sonni I; Alano R; Rettig M; Shen J; Armstrong W; Grogan T; Liu S; Czernin J; Calais J
    Sci Rep; 2024 Oct; 14(1):24411. PubMed ID: 39420060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
    Tosco L; Laenen A; Gevaert T; Salmon I; Decaestecker C; Davicioni E; Buerki C; Claessens F; Swinnen J; Goffin K; Oyen R; Everaerts W; Moris L; De Meerleer G; Haustermans K; Joniau S;
    BMC Cancer; 2018 Apr; 18(1):354. PubMed ID: 29606109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
    Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
    Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Chi KN; Agarwal N; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez Soto Á; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Deprince K; Naini V; Li J; Cheng S; Yu MK; Zhang K; Larsen JS; McCarthy S; Chowdhury S;
    N Engl J Med; 2019 Jul; 381(1):13-24. PubMed ID: 31150574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L;
    BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial.
    Roy S; Sun Y; Chi KN; Ong M; Malone S; Wallis CJD; Kishan AU; Malone J; Swami U; Gebrael G; Brown JR; Jia AY; Morgan SC; Saad F; Chowdhury S; Agarwal N; Spratt DE
    J Urol; 2024 Nov; 212(5):672-681. PubMed ID: 39058790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic Radiotherapy for Lesions Detected via
    Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
    Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
    BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography-staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial.
    Hölscher T; Baumann M; Kotzerke J; Zöphel K; Paulsen F; Müller AC; Zips D; Koi L; Thomas C; Löck S; Krause M; Wirth M; Lohaus F
    Eur Urol Oncol; 2022 Feb; 5(1):44-51. PubMed ID: 34785189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study.
    Hegele A; Häußermann R; Schultheis S; Skrobek L; Vink M; Hollwegs S; Ludwig M; Huwe P; Maywurm M; Bartsch-Polle A; Weber J; Thiemer M; Varughese D
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):414. PubMed ID: 39249593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial.
    Privé BM; Janssen MJR; van Oort IM; Muselaers CHJ; Jonker MA; de Groot M; Mehra N; Verzijlbergen JF; Scheenen TWJ; Zámecnik P; Barentsz JO; Gotthardt M; Noordzij W; Vogel WV; Bergman AM; van der Poel HG; Vis AN; Oprea-Lager DE; Gerritsen WR; Witjes JA; Nagarajah J
    BMC Cancer; 2020 Sep; 20(1):884. PubMed ID: 32928177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
    Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.
    Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
    Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.